Endometrial Neoplasms

"Endometrial Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.

Descriptor ID	D016889
MeSH Number(s)	C04.588.945.418.948.585 C13.351.500.852.762.200 C13.351.937.418.875.200
Concept/Terms	Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasm Neoplasm, Endometrial Neoplasms, Endometrial Endometrial Carcinoma Endometrial Carcinoma Carcinoma, Endometrial Carcinomas, Endometrial Endometrial Carcinomas Endometrial Cancer Cancer, Endometrial Cancers, Endometrial Endometrial Cancers Endometrium Cancer Cancer, Endometrium Cancers, Endometrium Cancer of the Endometrium Carcinoma of Endometrium Endometrium Carcinoma Endometrium Carcinomas Cancer of Endometrium Endometrium Cancers

Below are MeSH descriptors whose meaning is more general than "Endometrial Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Genital Neoplasms, Female [C04.588.945.418]
Uterine Neoplasms [C04.588.945.418.948]
Endometrial Neoplasms [C04.588.945.418.948.585]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Genital Diseases, Female [C13.351.500]
Uterine Diseases [C13.351.500.852]
Uterine Neoplasms [C13.351.500.852.762]
Endometrial Neoplasms [C13.351.500.852.762.200]
Urogenital Neoplasms [C13.351.937]
Genital Neoplasms, Female [C13.351.937.418]
Uterine Neoplasms [C13.351.937.418.875]
Endometrial Neoplasms [C13.351.937.418.875.200]

Below are MeSH descriptors whose meaning is related to "Endometrial Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Endometrial Neoplasms".

Endometrial Neoplasms
Carcinoma, Endometrioid

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Endometrial Neoplasms" by people in this website by year, and whether "Endometrial Neoplasms" was a major or minor topic of these publications.

Bar chart showing 94 publications over 29 distinct years, with a maximum of 8 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	1	3
1997	1	1	2
1998	1	0	1
1999	2	1	3
2001	1	1	2
2002	2	1	3
2003	2	1	3
2004	3	1	4
2005	1	0	1
2006	4	2	6
2007	1	0	1
2008	3	1	4
2009	4	1	5
2010	3	0	3
2011	3	0	3
2012	3	0	3
2013	5	1	6
2014	6	1	7
2015	2	1	3
2016	1	0	1
2017	3	1	4
2018	1	0	1
2019	4	0	4
2020	3	0	3
2021	2	0	2
2022	2	0	2
2023	8	0	8
2024	5	0	5
2025	1	0	1

Below are the most recent publications written about "Endometrial Neoplasms" by people in Profiles.

Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynecol Oncol. 2025 02; 193:119-129.

View in: PubMed
Matei DE, Enserro DM, Randall ME, Mutch D, Small W, DiSilvestro PA, Spirtos NM, O'Malley DM, Cantuaria GH, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland FR, Warshal D, Bonebrake A, Tewari KS, Tan A, Powell MA, Walker JL, Santin AD, Kim JH, Miller DS. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. J Clin Oncol. 2025 03 20; 43(9):1055-1060.

View in: PubMed
Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Gynecol Oncol. 2025 01; 192:40-49.

View in: PubMed
Kuchimanchi M, J?rgensen TL, Hanze E, Andr? T, Jain A, Berton D, Alsk?r O, Zub O, Oaknin A, Shahin MS, Koliadi A, Pothuri B, Krivak T, Pishchyk M, Segev Y, Backes FJ, Gennigens C, Bouberhan S, Zajic S, Melhem M, Buscema J. Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY. Br J Clin Pharmacol. 2025 Mar; 91(3):841-855.

View in: PubMed
Powell MA, Bj?rge L, Willmott L, Nov?k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Gropp-Meier M, Stuckey A, Boere I, Gold MA, Segev Y, Gill SE, Gennigens C, Sebastianelli A, Shahin MS, Pothuri B, Monk BJ, Buscema J, Coleman RL, Slomovitz BM, Ring KL, Herzog TJ, Balas MM, Grimshaw M, Stevens S, Lai DW, McCourt C, Mirza MR. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Aug; 35(8):728-738.

View in: PubMed
Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS, Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJ. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. J Immunother Cancer. 2024 01 19; 12(1).

View in: PubMed
Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, Borowsky M, Moroney J, Hendrickson AW, Backes F, Swisher E, Powell M, MacKay H. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 04 15; 130(8):1234-1245.

View in: PubMed
Barlin JN, Mahar B, Ata A, Cormier B, Michelin D, Salani R, Backes F, Levinson K, Cantrell LA, Weinberg L, Wagreich A, Savage D, Gasson C, Denniston K, Martin J, McElrath T, Timmins PF. Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma. Gynecol Oncol. 2024 01; 180:63-69.

View in: PubMed
Palmieri A, Hicks V, Aikman N, Borowsky M, Haggerty A, ElSahwi K. Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer. South Med J. 2023 10; 116(10):790-794.

View in: PubMed
Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 04; 7:e2200609.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement